Evidence map›Paper›PMID 40640839›Full record

ArticleWorld journal of surgical oncology2025

Construction of a column-line graphical model of poor outcome of neoadjuvant regimens for muscle-invasive bladder cancer based on NLR, dNLR and SII indicators.

Bo Hu, Longsheng Wang, Shanna Qu, Tao Zhang

Abstract read
In one paragraph

Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bo HuDepartment of Urology, Shandong Provincial Hospital, Affiliated to Shandong First Medical University, Jinan, 250021, China.
Longsheng WangDepartment of Urology, Shandong Provincial Hospital, Affiliated to Shandong First Medical University, Jinan, 250021, China.
Shanna QuCheeloo College of Medicine, Shandong University, Jinan, 250012, China.
Tao ZhangDepartment of Urology, Shandong Provincial Hospital, Affiliated to Shandong First Medical University, Jinan, 250021, China. chris2111@163.com.

Funding

the Natural Science Foundation of Shandong ZR2019PH095
6 · The paper itself

Abstract

backgroundTo study the effect and predict the value of neoadjuvant treatment regimen for muscle invasive bladder cancer (MIBC) by construction of a columnar graphical model of patients by neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), and systemic immune-inflammatory index (SII) indexes.

methods265 patients with MIBC included from May 2022 to May 2024 were retrospectively selected to receive neoadjuvant treatment regimen respectively with treatment effect assessed, among which those achieving complete response (CR), partial response (PR), or stable disease (SD) were included in responders group and those with progressive disease (PD) in non-responders group. Clinical data of both groups were compared, related factors affecting the poor outcome after neoadjuvant therapy for MIBC were analyzed by Logistic regression, ensued with analysis of predictive value of poor prognosis by construction of a columnar graph model based on the NLR, dNLR and SII indexes.

resultsA total of 265 patients with MIBC were included in this paper with a disease control rate (DCR) of 84.53% (224/265) after treatment with neoadjuvant regimen, among which 224 cases with controlled disease were involved in responders group and the remaining 41 cases with PD in non-responders group. Significant differences were observed between the two groups in terms of the degree of differentiation, tumor stage, NLR, dNLR and SII index levels (P < 0.05). After the diagnosis of covariance, the VIF values of the degree of differentiation and tumor stage were 5.535 and 5.582 respectively with a tolerance of 0.181 and 0.179, indicating that there existed a covariance problem (VIF value > 5) and could be moved out of the model followed by secondary analysis. Variables with P < 0.05 in the univariate factors were involved in the multivariate Logistic regression model with results showing that NLR, dNLR, and SII were all influential factors for the poor outcome of neoadjuvant regimens after treatment of MIBC (P < 0.05). Next, the column line graph, calibration curve and ROC curve graph were constructed. It was found that the AUC of the column line graph model in predicting poor outcome after neoadjuvant regimen for MIBC registered 0.995 (95% CI: 0.99-1.00), which was valuable in predicting poor outcome after neoadjuvant regimen for MIBC. CYFRA21-1, NMP22, and BTA were significantly higher in the poor response group than in the response group (P < 0.05), and CYFRA21-1, NMP22, and BTA showed a positive correlation with NLR, dNLR, and SII in both groups, respectively (P < 0.05).

conclusionThe neoadjuvant treatment program in patients with MIBC performed better, but some patients might still have a poor outcome with higher levels of NLR, dNLR and SII compared to those with a good outcome. In addition, the value of the combination of the three indicators in the prediction of the neoadjuvant treatment program displayed better performance, which was able to provide reference value for clinical decision-making.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphocytesMuscle NeoplasmsNeoadjuvant TherapyNeutrophilsUrinary Bladder NeoplasmsAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm InvasivenessPrognosisRetrospective StudiesSurvival RateMuscle-invasive bladder cancerNeoadjuvant treatment programNeutrophil-to-lymphocyte ratioSystemic immune-inflammatory index

Identifiers

PMID40640839
PMCPMC12247270

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.